Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Roche Provides Update on Leading Late-Stage Pharmaceutical Pipeline

By Pharmaceutical Processing | December 9, 2010

Roche today will provide an
update on its leading late-stage pipeline comprising twelve new molecular
entities in key therapeutic areas. The London
investor event will focus on major progress that has been achieved in recent
months with Roche’s late-stage pipeline assets in the areas of oncology and
CNS, as well as on further development plans of these potential breakthrough
medicines.

“Our goal is to continue delivering innovative medicines in
therapeutic areas of high unmet need and to bring true medical value to
patients. I am pleased that the glycine reuptake inhibitor and ocrelizumab –
two molecules with the potential to treat severe diseases such as schizophrenia
or multiple sclerosis are progressing to late-stage development”, said Hal
Barron, M.D., Head of Global Product Development and

Chief Medical Officer of Roche. “We also see that the
concept of Personalized Healthcare is becoming a reality for more and more of
our development projects. MetMAb and the BRAF inhibitor are two encouraging
examples for how personalized therapy could improve outcomes in lung cancer and
melanoma, respectively.”

Roche’s late-stage pipeline is progressing well with
potentially ten regulatory submissions of new molecular entities until the end
of 2013. Pipeline molecules such as T-DM1 and pertuzumab in breast cancer, GA101/RG7159
in NHL1 and CLL2 or the BRAF inhibitor RG7204 in melanoma are designed to move
the standard of care in treating these diseases and improve the chances of
longer survival or even cure. Other molecules such as the glycine reuptake
inhibitor RG1678 and ocrelizumab RG1594 have the potential to improve outcomes
in diseases such as schizophrenia or multiple sclerosis where new therapies are
urgently needed.

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE